Viking Therapeutics (VKTX) reported late Wednesday a Q1 net loss of $0.41 per diluted share, compared with a loss of $0.26 a year earlier.

Analysts polled by FactSet expected a loss of $0.33.

No revenue was reported for the quarter ended March 31. The company held cash, cash equivalents, and short-term investments of $851.9 million at March 31, compared with $902.6 million on December 31, 2024.

The company's shares were down more than 1% in recent after-market activity.